Strong 2Q And Fresh UK Investment Signal Few Brexit Blues at GSK
GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.
You may also be interested in...
Johnson & Johnson and Roche launched the big pharma quarterly reporting season. Next up are Novartis, Lilly, Merck, Bayer, GSK, Bristol-Myers Squibb, Amgen and Sanofi. Scrip offers some key points to watch for.
Britain's life sciences sector is compiling detailed game plan for September talks with the new Conservative government to promote its interests once the UK leaves the EU. All options are being considered – including possible establishment of a best-in-class regulatory agency in Britain.
GlaxoSmithKline is teaming up with the company formerly known as Google Life Sciences to create bioelectronic therapeutics, and hopes to have a product ready for market within seven years.